title: Attention-deficit/hyperactivity disorder: use of cognitive evoked potential (P300) to predict treatment response.
abstract: OBJECTIVE
  To evaluate the use of P300 in predicting treatment response to medicines in patients with Attention-Deficit/Hyperactivity Disorder (ADHD), and to confirm previous reports that 31-electrode mean auditory P300 amplitude (AA) predicts response to atomoxetine; and right fronto-central to parietal AA ratio predicts response to methylphenidate.
  
  
  METHODS
  Efficacy and P300 data from 58 children with ADHD enrolled in a double-blind crossover study using atomoxetine and methylphenidate were analyzed. Robust response was defined as 60% decrease from baseline in the ADHD rating scale. Response was alternately defined as greater than 50% decrease.
  
  
  RESULTS
  Pre-treatment mean 31-electrode AA>6.8 microV predicted response to atomoxetine using both definitions of response. Right fronto-central to parietal AA ratio did not predict response to methylphenidate. A previous report that methylphenidate responders differed from non-responders in pre-treatment AA at T8 was confirmed, and AA at T8>7.65 microV predicted response to methylphenidate. 31-electrode mean P300 visual latency (VL) also predicted response to atomoxetine, as previously reported with imipramine.
  
  
  CONCLUSIONS
  Mean AA predicts response to atomoxetine in ADHD patients. AA at T8 predicts response to methylphenidate. Such predictive tools may allow individually tailored choice of medicine in treatment of ADHD.
  
  
  CONCLUSIONS
  This allows a more informed decision of which medicine to use for a given patient.
authors.affiliation: Attention Disorders Institute, 44199 Dequindre, Ste. 311, Troy, MI 48085, USA. sangalrb@sbcglobal.net
authors.forename: R Bart
authors.initials: RB
authors.lastname: Sangal
authors.forename: Joanne M
authors.initials: JM
authors.lastname: Sangal
mesh_terms: D000161:Acoustic Stimulation / Q000379:methods; D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy / Q000503:physiopathology*; D001931:Brain Mapping; D002540:Cerebral Cortex / Q000187:drug effects / Q000503:physiopathology*; D002648:Child; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004569:Electroencephalography / Q000379:methods; D018913:Event-Related Potentials, P300 / Q000187:drug effects / Q000502:physiology*; D005260:Female; D007839:Functional Laterality; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use; D011237:Predictive Value of Tests; D011437:Propylamines / Q000627:therapeutic use; D012372:ROC Curve; D012016:Reference Values
chemical_list: D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D008774:Methylphenidate; D000069445:Atomoxetine Hydrochloride